Table 2

Vasculature modulation approaches

TreatmentImpact on tumorImpact on mAb tumor PKmAb/tumor modelSource
BevacizumabDecrease in tumor vasculature and permeability63% decrease in AUC (0–10 days)T84.66
LS174T		28
SorafenibDecrease in tumor vasculature and permeability41% decrease in AUC (0–7 days)T84.66
LS174T		131
Angiotensin IIIncrease in trans vascular pressure gradient, enhanced tumor blood flow40% increase in uptake 4 h after administrationCC49
LS174T		41
TNF-alpha administered intravenously (IV) or intra-tumorally (IT)Enhanced vasopermeability(IT) 200% increase at 3 h, 27% increase at 22 h
(IV) 100% increase at 3 h		Mab35
LOVO		42
InterferonEnhanced blood flow83% increase in uptake 1.5 h after administrationMEM136
WM-9		43
Interleukin 2 conjugateEnhanced vasopermeability275% increase in uptake 3 days after administrationTNT-1 F(ab′)2
ME-180		45
TNF-alpha conjugateEnhanced vasopermeability and blood flow213% increase in uptake 3 days after administrationTNT-1 F(ab′)2
ME-180		45
Interleukin 1 conjugateEnhanced vasopermeability and blood flow200% increase in uptake 3 days after administrationTNT-1 F(ab′)2
ME-180		45
Leukotriene-B4 conjugateEnhanced blood flow122% increase in uptake 3 days after administrationTNT-1 F(ab′)2
ME-180		45
Histamine conjugateEnhanced vasopermeability118% increase in uptake 3 days after administrationTNT-1 F(ab′)2
ME-180		45
Physalaemin conjugateEnhanced blood flow71% increase in uptake 3 days after administrationTNT-1 F(ab′)2
ME-180		45
Bradykinin conjugateEnhanced blood flow23% increase in uptake 3 days after administrationTNT-1 F(ab′)2
ME-180		45
PEP2-Ab conjugateEnhanced vasopermeability249% increase in uptake 3 days after administrationB72.3
LS174T		46
A22p-Ab conjugateEnhanced vasopermeability50%–100% increase in uptake at 3 and 12 h after administrationCetuximab/A459
Trastuzumab/SKOV3		49
iRGDEnhanced vasopermeabiltiy3,900% Increase at 3 h by ELISATrastuzumab
BT-474		48
Mannitol InfusionOsmotic opening of BBB234% and 32% increase in F(ab′)2 and mAb AUC (0.5–72 h)P1.17
LX-1 SCLC		58
Focused ultrasoundTransient disruption of BBB5,577% increase in uptake 2 h after administrationBevacizumab
U87 glioma		63
Angiopep-2-Ab conjugateRMT through BBB by LRP1 binding˜300% increase in tumor uptake 24 h after administrationTrastuzumab
BT-474		68
Human melanotransferrin-Ab conjugateRMT through BBB by LRP1 binding415% increase in tumor uptake 2 h after administrationTrastuzumab
MDA-MB-231-BRHER2/eGFP		69